Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Goodyear Tire & Rubber Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Goodyear Tire & Rubber Co trades at $6.1 (market cap $1.74B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 5.4× Goodyear Tire & Rubber Co's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| BIO | GT | |
|---|---|---|
Market Cap | $9.39B | $1.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $10.54 |
52-Week Low | $241.71 | $5.58 |
Enterprise Value | $9.14B | $9.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Goodyear Tire & Rubber (GT) is trading at $6.44, down 4.73% today, reflecting ongoing pressure from declining tire volumes and a challenging cost environment. The stock exhibits a bearish technical trend with oversold RSI levels, while fundamentals show a net loss of $1.72 billion in 2025 despite positive cash flow. Recent Q2 2026 results missed earnings expectations but beat revenue estimates, highlighting mixed operational performance amid market headwinds.
The outlook remains cautious with persistent profitability challenges and high debt levels offsetting low valuation multiples. Investment opportunity hinges on volume recovery and cost management improvements, but risks include sustained margin pressure and competitive threats. Analyst sentiment is mixed with a slight hold bias, underscoring the need for operational turnaround to drive shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
